Abstract
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Colon cancer treatment is dependent on stage at diagnosis. The current TNM (Tumour-Node-Metastasis) staging for the selection of patients for adjuvant chemotherapy needs additional prognostic and predictive biomarkers. Better decision-making for chemotherapy will result in reducing over- and under-treatment. We developed a new, easy to apply, practice-changing method to select colon cancer patients for adjuvant (chemo)therapy: the tumour-stroma ratio (TSR). The TSR distinguishes within stage II-III patients who will likely benefit of adjuvant (chemo)therapy and from those who will not. Objective: The study goal is to add the TSR to current routine pathology evaluation in addition to the TNM classification. Pathologists will be instructed for scoring the TSR in combination with a quality assessment program. An international multicentre study will validate the parameter prospectively. Methods: The study prepares for implementation of the TSR to current TNM guidelines, using routinely Haematoxylin and Eosin stained tumour tissue sections. Part 1. An E-learning module with a quality assessment program in the framework of the European Society of Pathology will be developed. This module will be used to assess the reliability and reproducibility of TSR, conducted by national and international pathologists. Part 2. Validation of the TSR in a prospective cohort of colon cancer pathological stage II-III patients in a multicentre setting. In total 1500 patients will be included. Results: The results of part 1 will be expected first half of 2019. For part 2, the inclusion was started end 2018 and will take 3 years, with an additional follow-up of 3 years. Conclusions: The main endpoints of this study are: Part 1. Instructed (international) pathologists who are able to reliably score TSR, resulting in low intra- and inter-observer variation. Part 2. Confirmation of significant survival differences for patients with a stroma-high tumour versus patients with a stroma-low tumour. Based on these findings modification in current treatment guidelines will be suggested. Clinical Trial: The Netherlands Trial Registry (NTR 7270). http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=7270

This publication has 24 references indexed in Scilit: